Seeking Alpha

Henry McCusker's  Instablog

Henry McCusker
Send Message
Editor and Publisher ... Henry enters his thirteen (13) year at RegMed Investors which aggregates, curates and creates bottom-line content of regenerative medicine - stem, gene and cell therapy news providing a "vetted" selection of relevant and high-impact synthesis. He was VP -... More
My company:
Scimitar Equity-Regenerative Medicine Investors
My blog:
Scimitar Equity Blog
View Henry McCusker's Instablogs on:
  • Aastrom (ASTM) Files 15 M Share Offering

    The last nights reported price was $0.37 per share with possible $12 - 13 M in proceeds

    Outstanding shares were 45.66 M and there will be 85.1 M post offering.

    The underwriter will now be Aegis Capital

    The Bottom Line: Finally, a lower share volume <25 M to 15 M> and a much lower pricing. JMP was dropped for Aegis for the offering.

    ASTM closed at $0.37. Expect this puppy to drop like a stone! How quickly can an over-night be priced (?) in a dropping market and at what price? My next question is ... "why put rouge on this ... blushing pig"!

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Jul 25 9:31 AM | Link | Comment!
  • NeoStem (NYSE MKT: NBS) Moves Trading To NASDAQ

    Ticker Symbol will remain "NBS"

    NeoStem (NBS) will move its listing from NYSE MKT to the NASDAQ Capital Market effective with the start of trading on 8/5/13. NeoStem will continue to trade under its existing ticker symbol "NASDAQ: NBS". NeoStem's common stock will continue to trade as NYSE MKT: NBS until the market close on 8/2/13.

    The Bottom Line: The NASDAQ will provide enhanced institutional and retail <the old adage of above $5> exposure and better trading. NBS will join comparable cell therapy and regenerative medicine companies: Celgene Corporation (NASDAQ:CELG), Harvard Bio (NASDAQ:HBIO), Osiris (NASDAQ:OSIR), Mesoblast ADR (OTC:MBLTY), bluebird bio (NASDAQ:BLUE), Stemline (NASDAQ:STML), Verastem (NASDAQ:VSTM), Wright-Medical (NASDAQ:WMGI), Shire ADR (NASDAQ:SHPG) and Cytori (NASDAQ:CYTX) on the NASDAQ.

    NBS closed at $7.47 … UP +$0.82 or +12.33% on strong volume of 663.6 K. As I had been stating NBS has been hitting to right field with 2 and 3 solid base hits. The key after any reverse is the keep swinging with base hits and NBS is delivering for the cell therapy sector. NBS is one of the few with positive catalysts - that stay in the <universe> park and we are only in the second inning with multiple batters on deck and base runners on 1st and 3rd.

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Tags: Expect more!
    Jul 23 8:29 AM | Link | Comment!
  • NeoStem (NYSE MKT: NBS) 1-for-10 Reverse Split – BUY

    Focuses market pricing to peers and comparables

    NeoStem, Inc. (NYSE MKT: NBS) effected a 1-for-10 reverse stock split of its common stock which will be effective for trading purposes as of the commencement of trading on July 16, 2013.

    As of that date, each 10 shares of issued and outstanding common stock and equivalents will be converted into 1 share of common stock. In addition, at the market open on 7/16/13, the common stock will trade under a new CUSIP number 640650 404 and the ticker symbol, NBS, will remain unchanged.

    • The number of authorized shares and the par value per share will remain unchanged;
    • No fractional shares will be issued in connection with the reverse stock split;
    • Holders of fractional shares will be paid out in cash <approximately $5K> for the fractional portion.

    NBS stockholder will receive instructions from its transfer agent, Continental Stock Transfer and Trust Company, as to procedures for exchanging existing stock certificates for new certificates or book-entry shares and for the receipt of cash proceeds in lieu of fractional shares.

    The Bottom Line: As a result of the reverse stock split, the exercise of each outstanding warrant and option would entitle the holder to 1/10 of a post reverse split share. The number of outstanding common shares will be reduced to approximately 19,664,790 from 196,643,748.

    The number of outstanding options and warrants will be adjusted accordingly, with outstanding options being reduced from 26,366,633 to approximately 2.6 M and outstanding warrants being reduced from 54,297,826 to approximately 5.4 M … "killing" most of all … the overhangs!

    NBS has been on a volume roll for these past four (4) days jumping from $0.56 to $0.58 to $0.61 finally settling at $0.58 on Thursday on strong volumes <293 K and 1.98 M, 2.34 M and 2.97 M>. It also - "seems" - that a 200 K block was bought which settled the $0.58 - short on the stock!

    NBS should open UP on Friday, 6/12/13. NBS has a pipeline of news to validate this event … to the future validating the reverse move!

    This common practice reverse will elevate the share pricing but also actualize the peer and comparable models to reflect the PCT business opportunity, the advancing AMR-001 trial and positioning of NBS as a sector leader.

    This "event" … also validates Dr. Robin Smith's … leadership of NBS and its role in fermenting the interests of hope in the sector and elevates NBS ability to attract greater institutional investment by adjusting the out-standing share count, over-hangs of options and warrants … which had been limited by the past pricing.

    The reverse should also provide eligibility for NBS to be included in the various indexes used as an unbiased barometer for the small-cap value segment delivering representation institutional investors' need for asset allocation decisions.

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Jul 12 8:27 AM | Link | Comment!
Full index of posts »
Latest Followers


  • ImmunoCellular (OTC BB: IMUC) files to Sell $13.8M of Units via Cowen
    Nov 30, 2011
  • Mid-Day Movers: BioTime (AMEX: BTX), Cytori (CYTX), Geron (GERN), Neuralstem (AMEX: CUR), ReNeuron (RENE.LON), ThermoGenesis (KOOL)
    Oct 26, 2011
More »

Latest Comments

Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.